Table 4 Lipid levels throughout the follow-up.
Lipid levels | Baseline | Month 3 | Month 6 | Month 9 | Month 12 |
|---|---|---|---|---|---|
All patients | (n = 514) | (n = 433) | (n = 388) | (n = 352) | (n = 355) |
Total cholesterol, mg/dl | 169 (23-427) | 168 (31-298) | 168 (36-340) | 171 (61-348) | 173 (54-297) |
Individuals with ≥ 240 mg/dl | 38 (7.3%) | 21 (4.8%) | 25 (6.4%) | 25 (7.1%) | 22 (6.2%) |
LDL cholesterol, mg/dl | 96 (20-320) | 95 (20-181) | 95 (15-210) | 95 (20-215) | 96 (20-189) |
Individuals with ≥ 160 mg/dl | 25 (4.8%) | 14 (3.2%) | 15 (3.8%) | 16 (4.5%) | 12 (3.4%) |
Total triglycerides, mg/dl | 133 (22-1637) | 134 (13-976) | 129 (37-881) | 139 (39-1708) | 128 (36-1664) |
Individuals with ≥ 200 mg/dl | 103 (20.0%) | 108 (24.9%) | 83 (20.6%) | 84 (23.8%) | 67 (18.8%) |
Individuals with ≥ 400 mg/dl | 17 (3.3%) | 22 (5.0%) | 11 (2.8%) | 12 (3.4%) | 13 (3.6%) |
Naive and ART-restarting patients (groups A and B) | (n = 130) | (n = 102) | (n = 87) | (n = 79) | (n = 69) |
Total cholesterol, mg/dl | 148 (53-285) | 161 (31-298) | 162 (61-340) | 167 (61-256) | 164 (69-266) |
Individuals with ≥ 240 mg/dl | 2 (1.5%) | 2 (1.9%) | 3 (3.4%) | 1 (1.2%) | 4 (5.8%) |
LDL cholesterol, mg/dl | 84 (20-211) | 91 (20-178) | 91 (15-210) | 94 (11-156) | 90 (20-157) |
Individuals with ≥ 160 mg/dl | 2 (1.5%) | 3 (3.4%) | 3 (3.4%) | 0 (0%) | 0 (0%) |
Total triglycerides, mg/dl | 115 (22-1637) | 118 (44-882) | 125 (37-680) | 113 (41-484) | 120 (36-378) |
Individuals with ≥ 200 mg/dl | 26 (5.0%) | 16 (3.7%) | 14 (3.6%) | 13 (3.7%) | 5 (1.4%) |
Individuals with ≥ 400 mg/dl | 3 (0.5%) | 4 (0.9%) | 2 (0.5%) | 2 (0.05%) | 1 (0.02%) |